The biologist who seeks funding to overcome the barriers of schizophrenia

Teresa Tarragó, CEO and co-founder of Iproteos

Teresa Tarragó, CEO and co-founder of Iproteos


Agencia SINC echoes the interest of pharmaceutical multinationals in Iproteos. Founded in 2011 by Teresa Tarragó, this biotechnology company is a spin-off of IRB Barcelona. Since then, Tarragó aimed to convert a molecule (IPR-19) discovered during her research into a drug. This molecule has great potential for the treatment of cognitive problems caused by schizophrenia.

Link to Agencia SINC